Abstract
The choice of a vaccine candidate against tropical theileriosis was based on key epidemiological considerations inherent to the main target endemic situation in Tunisia. One of the attenuated cell lines was retained as a vaccine candidate on the basis of small-scale trials testing the intrinsic safety aspects of the vaccine for the targeted animal categories in the dominant endemic situation where it will be used. The vaccine efficacy was confirmed in pilot vaccination campaigns using fresh culture and thawed cryopreserved vaccine doses delivered to the field using a new delivery system not requiring a cold chain. The potential benefit of the live attenuated Tunisian vaccine was evaluated using simple economical models.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
